CompanyManufactureTrainingContacts
RUS ENG
/ Catalog / Sweat Analysis Systems, Osmometers, Blood Gas, Hematology, Clinical Chemistry, Urinanalysis, Immunodiagnostics / Diabetes / DCA 2000+ Analyzer

DCA 2000+ Analyzer

Your Conversations about Diabetes Management make a real difference

HbA1c Testing

  • Monoclonal antibody method for HbA1c provides outstanding accuracy and precision
  • Correlation study shows 99% agreement with the HPLC method(1)
  • Near-patient results you can count on a CV of 2.6%* means your results are reliable(2)
  • National Glycohemoglobin Standardization Program (NGSP) certified method, as recommended by the ADA**

Microalbuminuria Testing

  • Microalbuminuria cartridge provides results for both albumin and creatinine
  • Instrument automatically calculates the A:C ratio, so you can use any specimen at any time

Talk about tight glycemic control to reduce risks.
Use HbA1c results to achieve therapeutic goals
  • The management goal for most patients with diabetes is an HbA1c result between 6% and 7%(1)
  • Any improvement in HbA1c levels can be significant(2,3)
  • "The predictive value of HbA1c for total mortality was stronger than that documented for cholesterol concentration, body mass index, and blood pressure."(4)
Use microalbuminuria results for telling signs of diabetic nephropathy
  • Unique in-office quantitative albumin:creatinine assay compensates for variations in urine concentration
  • Allows for early detection, close monitoring and timely interventions in nephropathy
Your patients without diabetes may also want to talk results
  • HbA1c testing may give you insight into mortality risks for your non-diabetic patients:(4) "Glycated hemoglobin seems to resemble blood pressure and blood cholesterol
    in terms of the continuous relation with cardiovascular risk."
  • As well, a recent study on urinary albumin levels showed a significant link between future cardiovascular mortality in postmenopausal women:(5) "Microalbuminuria is
    a reflection of vascular damage and a marker of early arterial disease in women from the general population."
HbA1c the most accepted metabolic indicator in diabetes
  • HbA1c testing should be performed routinely in all patients with diabetes(1). Measure every 3 months to determine whether a patient's metabolic control
    has remained continuously within the target range
Microalbuminuria the standard metabolic indicator for renal disease
  • Annual screening for microalbuminuria should begin at diagnosis in patients with type 2 diabetes and after 5 years' disease duration in type 1 diabetes(1)
  • "Analyte (albumin) / creatinine ratios should always be measured as part ofquantitative measurements if timed collections; overnight or 24-hour (samples)
    are to be avoided."(6)
Immediate results allow immediate interventions
  • A recent study indicated that "the immediate feedback provided by the [DCA 2000+ Analyzer] resulted in a significant decrease in HbA1c at
    6- and 12-month follow-up...."(7)
  • "Immediate access to HbA1c results meant that [healthcare professionals] could make more informed decisions about what changes in management
    should be implemented. Without immediate access to test results, changes in patient management might be sub-optimal."(8)
  • With in-office results, you can discuss next steps with your patients right away - Encourage your patients to continue their successful
    regimen, or motivate them to begin better managing their diabetes
User-friendly operation makes testing simple for you and your patients
  • HbA1c results in just 6 minutes
  • Microalbuminuria results in just 7 minutes
  • Requires only 1L of capillary/venous whole blood, or 40L of urine for a test
  • Totally self-contained reagent cartridges mean no reagent preparation, mixing or handling
What an HbA1c value means in terms of average blood glucose levels.
  • With a CV of 2.6%, the DCA 2000 is precise enough to detect even the smallest changes
    in glycemic control
  • DCCT results say:(1)Tight glycemic control (~7%)
    leads to reductions in:Eye disease -76%
    Nerve disease -60%Cardiovascular disease -41%
    Kidney disease -39%
  • UKPDS results say:(2)1% decrease in HbA1c leads to 35% reduction
    in risk of microvascular complications

Copyright 2001-2003 Holding ANTARES

Tel.: +7 (495) 943-92-54
Tel./Fax: +7 (495) 648 15 71
E-mail: antares@antaresholding.ru 

Development and support 
Prorock Wed-soft